Sera of Overweight Patients Alter Adipogenesis and Osteogenesis of Bone Marrow Mesenchymal Stromal Cells, a Phenomenon that also Persists in Weight Loss Individuals

Angela Ferone¹, Giovanni Messina², Nicola Alessio³, Stefania Capasso©, Marilena Cipollaro¹, Marcellino Monda³, Gianfranco Peluso³, Umberto Galderisi³ and Giovanni Di Bernardo*²

¹Department of Experimental Medicine, Biotechnology, Medical Histology and Molecular Biology Section, Second University of Naples, Naples, Italy
²Department of Experimental Medicine, Human Physiology and Unit Of Dietetic and Sports Medicine Section, Second University of Naples, Naples, Italy
³Institute Bioscience and Bioresources; Cnr; Naples, Italy

Abstract

**Background:** Overweight and obesity represents a complex interaction of genetics, diet, metabolism, and physical activity. Abnormal or excessive fat accumulation increases the risk of pathologies, such as heart disease, diabetes, and high blood pressure.

**Methods and results:** In a previous paper, we investigated the influence of overweight individuals’ sera on in vitro biology of mesenchymal stromal cells, which contain a subpopulation of multipotent stem cells. This report extended the study by evaluating effects of sera collected from weight loss patients on stromal cultures.

**Results:** Sera showed that an increase in fat mass induces physiological changes that negatively impact on stromal cell adipogenesis and osteogenesis with a bias toward adipocyte differentiation. This phenomenon occurred with sera from overweight patients and persisted also with sera of individuals that underwent weight loss. Significant changes in obesity-related cytokines were detected in sera of overweight and weight loss compared to healthy weight individuals. These changes may explain some of the biological effects detected on stromal stem cell functions.

**Keywords:** MSCs; Adipogenesis; Osteogenesis; Overweight; Weight loss; Cytokines; Senescence

Introduction

Overweight and obesity are defined as abnormal or excessive fat accumulation in the adipose tissue, resulting in a high risk to health. On the other hand, visceral obesity is defined by the presence of excess adipose tissue in the abdominal cavity, and is an independent risk factor for several diseases. A common way to measure individuals’ obesity is the body mass index (BMI). The metric formula, a person’s weight (in kilograms) divided by the square of his or her height (in metres) is used to calculate BMI. Therefore, individuals with a body mass index between 18 and 25 are considered having healthy weight; people with a BMI between 25 and 29 are considered overweight; and people with a BMI of 30 or more are generally defined as obese. Overweight and obesity are major risk factors for a number of chronic diseases, including dyslipidemia, diabetes, cardiovascular diseases, and cancer. These conditions can shorten life span.

Lifestyle modification, consisting of a reduction in energy intake, an increase in energy consumption, and behavioural strategies to support these transformations, is the keystone of weight loss therapy. Many short-term studies have shown that modest weight loss of approximately 5–10% of initial weight can be associated with improvement or, in some cases, regression of obesity-related disorders [1].

Cytokines appear to be major regulators of adipose tissue functions. They can regulate homeostasis, metabolism, and interplay with immune system. In particular, obesity is associated with chronic inflammation [2]. It is well known that, in overweight and obese people, the level of various circulating cytokines, hormones, and other signalling molecules are dysregulated due to presence of an inflammatory status [3]. This may affect the functions of several organs and tissues, including the stem cell niches, which are specific tissue regions that house stem cells and control their self-renewal and lineage production by modulating the concentration of signalling molecules, such as hormones, cytokines, and growth factors [4].

The stroma of mammalian bone marrow is composed of several different elements that support hematopoiesis and bone homeostasis [5]. It includes several types of differentiated cells, progenitors, and stem cells. Among these are mesenchymal stem cells (MSCs), which are primordial cells of mesodermal origin that give rise to adipocytes, chondrocytes, osteocytes, and smooth muscle cells [5,6]. We have previously demonstrated that the dysregulated factors circulating in serum affected the differentiation potential of bone marrow MSCs in overweight people [7]. Indeed, that study showed that in vitro incubation of MSCs with sera of overweight individuals promotes MSC adipogenesis while impairing osteogenesis [7]. There are reports showing that some diseases such as diabetes and obesity may induce a permanent or semi-permanent impairment of stem cell niche functions that is not strictly associated with the acute phase of the disease. In this way, it remains to be determined if negative effects of sera from overweight people still persist after weight loss [8]. In a recent study, Baptista et al. demonstrated that MSCs isolated from adipose tissue of overweight and obese patients showed a permanent or semi-permanent impairment of MSC niche function. In particular, it was observed that these stem cells had a decreased ability to differentiate into adipocytes and osteocytes when cultured with sera from overweight and obese people [9].

Citation: Ferone A, Messina G, Alessio N, Capasso S, Cipollaro M. et al. (2016) Sera of Overweight Patients Alter Adipogenesis and Osteogenesis of Bone Marrow Mesenchymal Stromal Cells, a Phenomenon that also Persists in Weight Loss Individuals. J Stem Cell Res Ther 6: 347. doi:10.4172/2157-7633.1000347

Copyright: © 2016 Ferone A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
tissue of individuals who previously had obesity showed more in vitro adipogenic potential than those with the same cells type obtained from healthy weight patients [9]. Based on this premise, this study followed overweight people during their programmed diet schedule for losing weight and evaluated the in vitro behaviour of healthy MSCs incubated with sera obtained at the beginning of diet, then three and six months later when their reached healthy BMI.

**Materials and Methods**

**Ethical approval**

The experimental procedures followed the rules approved by the Ethics Committee of the Second University of Naples. Specifically, patients were informed of the research and gave permission for the use of serum samples and bone marrow harvests.

**Serum samples**

Serum samples were collected from three adult men of healthy weight (body mass index (BMI)<25) and three adult men with BMIs>25 (overweight), after informed consent. These latter patients were followed during a weight loss treatment for six months. Serum samples were collected at the first medical visits, then three and six months later. Whole blood samples (10 ml) were collected from patients in Vacutainer test tubes (BD Bioscience, Italy). After collection, the samples were left undisturbed to allow the blood to clot at room temperature. The clots were removed by centrifuging at 1,000 rpm for 10 minutes in a refrigerated centrifuge. The resultant supernatants were designated sera and were collected with a Pasteur pipette. The sexual and age information of patients and healthy people are shown in supplementary file 1.

**MSC cultures**

Bone marrow samples were obtained from three healthy donors. We separated cells using a Ficoll density gradient (GE Healthcare, Milan, Italy), and the mononuclear cell fraction was collected and washed in PBS. We seeded 1 to 2.5 × 10^5 cells/cm² in alpha-minimum essential medium (alpha-MEM) containing 10% fetal bovine serum (FBS) and 1 ng/ml basic fibroblast growth factor (bFGF). After 72 hours, non-adherent cells were discarded and adherent cells were further cultivated to confluence. Cells were then incubated for seven to ten days in growth medium to reach confluence and extensively propagated for the experimental plan, as shown in Figure 1. We verified that, under our experimental conditions, the bone marrow stromal cultures contained MSCs that fulfilled the criteria proposed to define MSCs (CD90+, C73+, CD105, CD45-) [10]. All experiments were carried out on MSC cultures at passage 3.

For evaluation of the patients’ serum effects on in vitro MSC functions, cells were incubated for 72 hours in alpha-MEM containing 10% patients’ serum and 1 ng/ml β-FGF. At the end of that time, cultures were used for programmed analysis. All cell culture reagents were obtained from Euroclone Life Sciences (Milan, Italy) and Hyclone (UT, Logan, USA) unless otherwise stated.

**Cell cycle analysis**

For each assay, cells were collected and fixed in 70% ethanol, followed by PBS washes, and finally were dissolved in a hypotonic buffer containing propidium iodide. Samples were acquired on a Guava EasyCyte flow cytometer (Merck Millipore Italy) and analyzed with a standard procedure using EasyCyte software.

**Annexin V assay**

Apoptotic cells were detected using a fluorescein-conjugated Annexin V kit on a Guava EasyCyte flow cytometer, following the manufacturer’s instructions. The kit uses two separate dyes (Annexin V and 7AAD) to identify several types of apoptotic and non-apoptotic cells. Annexin V (red) binds to phosphatidylserine on the external membrane of apoptotic cells, while 7AAD (blue) permeates and stains DNA of late-stage apoptotic and dead cells. Staining allows the identification of three cell populations: non-apoptotic cells (Annexin V- and 7AAD-), early apoptotic cells (Annexin V+ and 7AAD-), and late-apoptotic or dead cells (Annexin V+ and 7AAD+). In our experimental conditions, early and late apoptotic cells were grouped together.
Senescence-associated beta-galactosidase assay

Cells were fixed for ten minutes using a solution containing 2% (v/v) formaldehyde and 0.2% (w/v) glutaraldehyde. Cells were washed with PBS and then incubated at 37°C for at least two hours with a staining solution (citric acid/phosphate buffer (pH 6), K4Fe(CN)6, K3Fe(CN)6, NaCl, MgCl2, and X-Gal). The percentage of senescent cells was calculated by the number of blue cells (β-galactosidase positive cells) out of at least 500 cells in different microscope fields.

Adipogenic differentiation

MSCs were preliminarily incubated for 72 hours in growth medium containing 10% of patients' sera (healthy individuals, overweight patients at first visit, then after three and six months of diet regimen). Then cultures were stimulated for 15 days in hMSC mesenchymal stem cell adipogenic differentiation medium (catalog n. PT-3004-KT-Lonza, Walkersville, MD, USA). The medium contains insulin (recombinant), dexamethasone, indomethacin, and 3-isobutyl-1-methyl-xanthine (IBMX). Lipid droplets were revealed by staining with Oil Red O.

Osteogenic differentiation

After 72 hours of human serum treatment, as reported for adipogenesis, cultures were incubated for 15 days in hMSC mesenchymal stem cell osteogenic differentiation medium (catalog n. PT-3002-KT-Lonza). The medium contains dexamethasone, ascorbate, and glycercophosphate. Calcium deposits in differentiated osteocytes were revealed by staining with alizarin red.

RNA extraction and RT-qPCR

Total RNA was extracted from cell cultures using TRIREAGENT (Molecular Research Center Inc., Cincinnati, OH, USA) according to the manufacturer’s protocol. The mRNA levels of osteocyte differentiation markers (Osterix and Osteopontin) were measured by RT-qPCR amplification, as previously reported [11].

Sequences for mRNAs from the nucleotide data bank (National Center for Biotechnology Information, Bethesda, MD, USA) were used to design primer pairs for RT-PCR reactions (Primer Express, Applied Biosystems, Carlsbad, CA, USA) as previously reported [7]. Appropriate regions of GAPDH cDNA were used as controls. Each RT-qPCR reaction was repeated at least three times. A semi-quantitative analysis of mRNA levels was conducted using the GEL DOC UV SYSTEM (Bio-Rad). Primer sequences were designed with Primer Express software (Invitrogen, Milan, Italy).

Cytokine array

The profile of the relative levels of 19 cytokines in the serum samples harvested from the healthy weight, overweight, and weight loss groups was determined using the Human Obesity Antibody Array C1 (RayBiotech, Norcross, GA USA). The nitrocellulose membranes provided by the manufacturer contain 19 capture antibodies spotted in duplicate on the surface. Each membrane also included four pairs of positive control spots and two pairs of negative control spots. A total of 2 ml of the serum samples for each of the three experimental groups was used for hybridization. Hybridizations and signal measurements were performed following the manufacturer’s instructions. Array signals were acquired using the Chemidoc system (Bio-Rad Company, Hercules, CA, USA) and the associated software QuantityOne. Array images used for signal quantification (expressed as pixel density) were produced through camera exposure for five minutes. All the membranes were processed simultaneously. All hybridizations were repeated twice.

Statistical analysis

Statistical significance was evaluated using ANOVA analysis followed by Student’s t and Bonferroni’s tests. A mixed-model variance analysis was used for data with continuous outcomes. All data were analysed with a GraphPad Prism version 5.01 statistical software package (GraphPad, CA, USA).

Results

Table 1 shows the BMI values of overweight patients at their initial medical examinations, and then three and six months later. The main blood serum and biochemical indicators were in the normal range for all the patients at each examination.

In a previous paper, we demonstrated that in vitro biological functions of MSCs were negatively affected by incubation with sera obtained from overweight individuals. We decided to ascertain if loss of weight might reduce the negative impact on MSC biology. We analysed the cell cycle profile, apoptosis, senescence, and differentiation potential of MSCs incubated with sera of overweight people and sera of the same individuals following their loss of weight. As reference, we evaluated the properties of MSCs incubated with sera of individuals with healthy BMI (<25).

To generate a more complete picture of changes occurring in overweight patients following diet regimen, we assessed a panel of circulating cytokines at first medical inspection and later on.

The overall research strategy is depicted in Figure 1. The sera from healthy people, overweight patients at the first visit, and then three and six months later was called HS, OS, LS3, and LS6, respectively.

Cell cycle profile, apoptosis, and senescence unaffected by overweight serum incubation

The cell cycle status of stromal cultures did not change following incubation with sera from overweight patients compared with sera of healthy individuals. Also sera collected after loss of weight did not modify cell cycle profile (Figure 2).

The Annexin assay did not show a significant difference in the percentage of apoptotic cells in cultures treated with LS3 and LS6 as compared to OS and HS treatment (Figure 3). Moreover, the treatment with LS3 and LS6 did not change the senescence process as detected with acid beta-galactosidase assay, as shown in Figure 4.

Adipogenic and osteogenic differentiation

Adult men and women have 3.0 – 4.5 kg of fat mass, and in severely obese people, adipose tissue can constitute 45 kg or more of body weight. In obese status, an increment in fat mass could only result from engagement and differentiation of adipocyte progenitor cells [12]. In

| BMI Index | Initial Medical | Three month | Six month |
|-----------|----------------|-------------|-----------|
| Examination | later | later | | |
| Patient A | 34.2 | 29.3 | 25.7 | |
| Patient B | 37 | 32.2 | 27.8 | |
| Patient C | 35 | 30.3 | 25.2 | |
| Average | 35.4 | 30.6 | 26.2 | |

Table 1: Body Mass Index. The table shows BMI of patients at initial medical examination, three and six months later.
Figure 2: Cell cycle analysis. The picture shows a representative FACS analysis of HS, OS, LS3 and LS6 treated MSCs. The percentage of different cell populations (G1, S and G2/M) is indicated. Data are expressed with standard deviations. HS: Healthy Weight Serum; OS: Overweight Serum; LS3 and LS6: Sera from weight loss patients three and six months after first medical examination, respectively.

Figure 3: Analysis of apoptosis. Panel A: Flow cytometry analysis of apoptosis with Annexin assay. The assay allows the identification of early (Annexin V + and 7ADD-) and late apoptosis (Annexin V + and 7ADD +). Nevertheless, apoptosis is a continuous process and we calculated the percentage of apoptosis as the sum of early and late apoptotic cells, to avoid a discretional separation between early and late apoptosis. Panel B: The graph shows mean percentage value of apoptotic cells (± SD, n = 3). HS: Healthy Weight Serum; OS: Overweight Serum; LS3 and LS6: Sera from weight loss patients three and six months after first medical examination, respectively.
a previous paper, we investigated the effect of OS serum on MSCs. OS treatment induced a higher percentage of differentiated adipocytes than HS. We aimed to evaluate whether this negative effect persists after a weight loss.

Indeed, the increase in percentage of differentiated adipocytes remained also following incubation with sera of weight loss individuals compared with healthy sera treatment (Figure 5). Alizarin red staining did not exhibit significant differences in the osteogenesis process of MSCs incubated with HS, OS, LS3, and LS6, as shown in Figure 6. To gain further insights into osteocyte differentiation, we performed RT-
qPCR expression analysis of early and late osteocyte differentiation markers [13-19]. This analysis showed that incubation of sera from overweight individuals altered the correct osteogenic differentiation of MSCs. Indeed, as expected, MSCs incubated with HS serum and then induced to differentiate into osteocytes showed an upregulation of Osterix and Osteopontin mRNAs, which are early and late maturation markers, respectively (Figure 6). Upregulation of Osterix levels was observed also in MSCs treated with OS, LS3, and LS6. In contrast, Osteopontin levels were elevated in undifferentiated MSCs treated with OS, LS3, and LS6, but declined to almost undetectable levels after induction of differentiation. This suggests that late differentiation is impaired.

Analysis of cytokine expression profiles in weight loss sera

Adipose tissue is an endocrine organ with a complex function in total body homeostasis with a key role in metabolism, food intake, and immunomodulation. Adipokines and cytokines are the signalling factors released from this tissue and play a role in maintaining health, but can contribute to pathologies associated with obesity.

We used the Human Obesity Antibody Array C1 (RayBiotech, Norcross, GA USA) to accurately profile the expression of the most cytokines involved in obesity. The expression levels of some cytokines did not differ significantly between the HS, OS, LS3, and LS6 samples. Others were expressed at very low levels in all experimental conditions and this did not allow their quantification. Some others showed significant changes in OS, LS3, and LS6 compared with HS serum. In order to better organize changes in expression profiles, we grouped cytokines in four classes, as shown in Table 2.

Class A contains cytokines that increased in OS compared to HS, then declined three months after first medical inspections before finally increasing again at six months. Class B presents cytokines that increased in OS serum and then declined progressively at LS3 and LS6. Class C has factors that increased in OS, then declined at LS3 without further decrease at LS6. Finally, Class D contains cytokines with variable expression patterns.

Some cytokine expression trends are in good agreement with physiological changes expected in overweight individuals that follow a diet regimen to lose weight. Others are at odds with this hypothesis as argued in detail in the discussion section.

Discussion

Adipose tissue behaves as an endocrine organ able to produce a variety of adipokines as well as proinflammatory chemokines and cytokines. Consequently, obesity is characterized from a condition of low-grade chronic inflammation to strikingly elevated concentrations of pro-inflammatory cytokines [13,14].

We previously showed that sera from overweight individuals might alter the differentiation potential of MSCs with a bias toward adipocytes differentiation. This was surprising since the analysed individuals did not show frank obese status and did not have any obese-related pathology, such as diabetes or cardiovascular diseases. Our data suggested that overweight status is not a mere aesthetic issue but may have consequences for patient health.

We aimed to evaluate if the “vicious circle” based on adipogenic promoting factors present in sera of overweight individuals, which in turn induces the release of other pro-adipogenic factors that may be arrested with diet regimen leading to weight loss. We then evaluated the effect of sera from previously overweight subjects on the differentiation potential of the MSC population. This research represents a pilot study due to the small number of evaluated cases.
investigation is necessary. MCP-1 and IL-6 levels significantly increased in overweight people compared to controls as inflammation status. It should be noted that MCP-1 and IL-6 were not constant at LS6 compared to OS. This conforms with a reduction of three and six months, which were our time points.

To our surprise, sera from weight loss individuals also promoted adipogenesis and impaired osteocyte differentiation process. This effect was cell-commitment and cell differentiation specific, since cell cycle status, apoptosis, and senescence were not affected.

This finding may suggest that overweight status may induce epigenetic changes [15], which persist even after weight loss. It should be evaluated whether this "memory" can persist for periods longer than three and six months, which were our time points.

It remains to define:

i) The type of epigenetic modifications and other permanent physiological events;
ii) Which cell types undergo these persistent alterations; and
iii) The consequences on body physiology of these modifications.

We started to address this last issue by analysing changes in the levels of obesity-related circulating cytokines in overweight and weight loss subjects compared to healthy weight people.

To create a clearer picture of occurring changes, cytokines were classified into three groups: pro-inflammatory cytokines, cytokines related to metabolism, and cytokines related to proliferation, survival, and cellular differentiation. The observed changes allowed a further classification into four classes (A, B, C and D) with different expression expression patterns.

**Cytokines related to inflammation**

RANTES, IL-6, and MCP-1 levels were lower at LS3 and remained decreased more in weight loss individuals than in the controls. Further described for obese patients. It is unclear why MCP-1 and IL-6 levels are associated with cardiovascular diseases [16]. This data is in good agreement with a reduction of inflammatory status.

Changes in the expression profile of other inflammatory cytokines such as MSP-α and IL-8 cannot be directly linked to a reduction of inflammation as hypothesised that it may occur in people undergoing weight loss [18-20]. Further studies are needed.

**Cytokines related to metabolism**

We obtained conflicting data on the cytokines that modulate metabolism. While changes in leptin and adipin correlate with the literature, RESISTIN and ADIPONECTIN showed more complex expression patterns.

Leptin is an important hormone that shapes appetite and hunger signals and it is secreted primarily in fat cells, as well as the stomach, heart, placenta, and skeletal muscles. Leptin decreases hunger and usually also correlates to fat mass, as the more fat is present the more leptin is produced [21]. In this way, our data evidenced an increase of leptin in overweight patients compared to control and its decrease during weight loss.

Cytokines related to metabolism important roles in tissue remodelling and are implicated in a number of diseases related to inflammation [16]. Therefore, the decrease of their levels during weight loss is in agreement with a reduction of inflammatory status.

Results showed a down regulation of PAI levels, a protein that is associated with cardiovascular diseases [17]. This data is in good agreement with a reduction of inflammatory status.

Changes in the expression profile of other inflammatory cytokines such as MSP-α and IL-8 cannot be directly linked to a reduction of inflammation as hypothesised that it may occur in people undergoing weight loss [18-20]. Further studies are needed.

**Cytokines related to metabolism**

We obtained conflicting data on the cytokines that modulate metabolism. While changes in leptin and adipin correlate with the literature, RESISTIN and ADIPONECTIN showed more complex expression patterns.

Leptin is an important hormone that shapes appetite and hunger signals and it is secreted primarily in fat cells, as well as the stomach, heart, placenta, and skeletal muscles. Leptin decreases hunger and usually also correlates to fat mass, as the more fat is present the more leptin is produced [21]. In this way, our data evidenced an increase of leptin in overweight patients compared to control and its decrease during weight loss.

Complement plays important roles in host immune defences, and recent studies suggest that adipose tissue is an important site of production for some complement proteins like Adipsin (Factor D), a rate-limiting enzyme in the alternative complement activation pathway. Levels of alternative pathway complement components are determined in part by factors that influence body weight and by weight modifications, possibly due to changes in production in adipose tissue or at other sites [22]. Indeed, body weight reduction connotes lower levels of Adipsin at LS3 and LS6.

Resistin (or ‘resistance to insulin’) has been suggested to be an...
important link between obesity and metabolic syndrome. Nevertheless, its role in human obesity remains unclear. Indeed, studies in humans are controversial: in several investigations, serum resistin was reported to be related to fat mass [23] while other reports reveal no correlations to BMI and per cent body fat [24].

During weight loss, we observed a decrease in resistin as if its level was associated with fat mass. Nevertheless, resistin level was very high in controls compared to overweight, LS3, and LS6.

Only a few studies have examined changes in adiponectin levels with body weight reduction in humans [25]. In these investigations, large losses of body weight resulted in significant increases in plasma adiponectin concentrations. However, whether smaller losses of body weight elicit a change in adiponectin concentrations is unclear. In LS3 and LS6 sera, contrarily, we observed a decrease of adiponectin values.

Cytokines related to proliferation, survival, and cellular differentiation

Endogenous PDGFs (PDGFAA, PDGFB, and PDGFAB) have the ability to influence the proliferation and differentiation of human adipose derived stem cells and progenitors. Down regulation of PDGFs levels in LS3 and LS6 suggests that weight loss is associated with a reduced proliferation stimulus to adipocytes [26].

In humans, there are six IGFBP genes encoding a family of highly conserved proteins (including IGFBP1 and IGFBP-2) that have high affinity binding for the insulin-like growth factors (IGFs). Secretion of IGFBP-1 and IGFBP-2 is suppressed by insulin and diminished with increasing obesity. Whereas our data are in contrast with the literature [27,28] further investigation will be needed to understand the decline in LS subjects.

Conclusion

The findings of this study indicate that the increase in fat mass induces physiological changes that negatively affect the functions of stem cells involved in adipogenesis and osteogenesis. This phenomenon occurs in overweight people and persists for several months after weight loss. On this premise, physicians should suggest that overweight patients be cautious about their health even if they do not exhibit any obesity-related diseases.

Suggestions to improve lifestyle and weight loss are even more compelling considering the significant changes in obesity related cytokines we detected.

To gain further insights on the complex phenomena documented here, we aim to prosecute this pilot study with a larger cohort of patients.

Acknowledgments

We are greatly indebted to Mrs. M.R. Cipollaro for their administrative assistance. This research was partially supported by grant from the Ministero dell'Universita' e Ricerca Scientifica PRIN 2012 “Nanotecologie per variare i programmi di sviluppo osseo nella parete vasale per la prevenzione e trattamento delle patologie associate alla calcificazione ectopica arteriosa” to GDB.

References

1. Ambbea EJ (2013) Associations between weight loss and regain, cytokine concentration, and insulin resistance among overweight/obese adults pp 137.

2. Coppack SW (2001) Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 60: 349-356. [PubMed]

3. Galic S, Oakhill JS, Steinberg GR (2010) Adipose tissue as an endocrine organ. Mol Cell Endocrinol 316: 129-139. [PubMed]

4. Hsu YC, Fuchs E (2012) A family business: stem cell progeny join the niche to regulate homeostasis. Nat Rev Mol Cell Biol 13: 103-114. [PubMed]

5. Nardi NB, Meirelles DSL (2006) Mesenchymal stem cells: isolation, in vitro expansion and characterization. Handb Exp Pharmacol 174: 249-282. [PubMed]

6. Sethe S, Scott A, Stolzing A (2006) Aging of mesenchymal stem cells. Ageing Res Rev 5: 91-116. [PubMed]

7. Bernardo DG, Messina G, Capasso S, Gaudio DS, Cipollaro M, et al. (2014) Sera of overweight people promote in vitro adipocyte differentiation of bone marrow stromal cells. Stem Cell Res Ther 5: 4. [PubMed]

8. Perez LM, Suarez S, Bernal A, Lucas BD, Martin SN, et al. (2016) Obesity-driven alterations in adipose-derived stem cells are partially restored by weight loss. Obesity 24: 661-679. [PubMed]

9. Baptista LS, Silva DKR, Pedrosa DCS, Silva CDC, Carneiro JR, et al. (2009) Adipose tissue of control and ex-obese patients exhibit differences in blood versus resident and resident mesenchymal stem cell population. Obes Surg. 19: 1304-1312. [PubMed]

10. Dominici M, Blanc KL, Mueller I, Cortenbach IS, Marini F, et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315-317. [PubMed]

11. Huggett J, Dheda K, Bustin S, Zumla A (2005) Real-time RT-PCR normalisation; strategies and considerations. Genes Immun 6: 279-284. [PubMed]

12. Mansilla E, Aquino VD, Zambon D, Marín GH, Martíne K, et al. (2011) Could metabolic syndrome, lipodystrophy, and aging be mesenchymal stem cell exhaustion syndromes. Stem Cells Int 2011: 943216. [PubMed]

13. Hellbronn LK, Campbell LV (2008) Adipose tissue macrophages, low grade inflammation and insulin resistance in human. Curr Pharm Des 14: 1225-1230. [PubMed]

14. Molica F, Morel S, Kwak BR, Jeanrenaud F, Stieffens S (2015) Adipokines at the crossroad between obesity and cardiovascular disease. Thromb Haemost. 113: 553-566. [PubMed]

15. Ozkul Y, Galderisi U (2016) The Impact of Epigenetics on Mesenchymal Stem Cell Biology. J Cell Physiol [PubMed]

16. Karlqvist JH, Akerfeldt T, Gunnberg L, Swenne CL, Larsson AS (2012) Serum MMP-9 and TIMP-1 concentrations and MMP-9 activity during surgery-induced inflammation in humans. Clinical chemistry and laboratory medicine 50: 1115-1119. [PubMed]

17. Aso Y (2007) Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Frontiers in bioscience: a journal and virtual library. 12: 2957-2966. [PubMed]

18. Yasuda K, Ueda Y, Ozawa M, Matsuda T, Kinashi T (2016) Enhanced cytotoxic T-cell function and inhibition of tumor progression by Mst1 deficiency. FEBS letters 590: 68-75. [PubMed]

19. Katagiri K, Katakai T, Ebisuno Y, Ueda Y, Okada T, et al. (2009) Mst1 controls lymphocyte trafficking and interstitial motility within lymph nodes. The EMBO journal 28: 1319-1331. [PubMed]

20. Harada A, Sekido N, Akahoshi T, Wada T, Mukaida N, et al. (1994) Essential involvement of interleukin-8 (IL-8) in acute inflammation. J Leukoc Biol 56: 559-564. [PubMed]

21. Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in mammals. Nature. 395: 763-770. [PubMed]

22. Pomeroy C, Mitchell J, Eckert E, Raymond N, Crosby R, et al. (1997) Effect of body weight and caloric restriction on serum complement proteins, including Factor Dradipas: studies in anorexia nervosa and obesity. Clinical and experimental immunology. 108: 507-515. [PubMed]

23. Yannakoulia M, Yianakouris N, Bluher S, Matalas AL, Klimis-Zacas D, et al. (2003) Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. The Journal of clinical endocrinology and metabolism. 88: 1730-1736. [PubMed]

24. Silha JV, Kreek M, Skhara JV, Suchard P, Nyomba BL, et al. (2003) Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. European journal of endocrinology / European Federation of Endocrine Societies 149: 331-335. [PubMed]
25. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, et al. (2001) Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. The Journal of clinical endocrinology and metabolism 86: 3815-3819. [PubMed]

26. Josh F, Tobita M, Tanaka R, Orbay H, Ogata K, et al. (2013) Concentration of PDGF-AB, BB and TGF-beta1 as valuable human serum parameters in adipose-derived stem cell proliferation. Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 80: 140-147. [PubMed]

27. Rajwani A, Ezzat V, Smith J, Yuldasheva NY, Duncan ER, et al. (2012) Increasing circulating IGFBP1 levels improves insulin sensitivity, promotes nitric oxide production, lowers blood pressure, and protects against atherosclerosis. Diabetes 61: 915-924. [PubMed]

28. Hoeflich A, Russo VC (2015) Physiology and pathophysiology of IGFBP-1 and IGFBP-2 - consensus and dissent on metabolic control and malignant potential. Best Pract Res Clin Endocrinol Metab 29: 685-700. [PubMed]